POET Technologies Trades Below Its $21 Capital Raise as Legal and Execution Risks Overshadow AI Photonics Story

POET raised $400M for photonics expansion, but stock trades below issue price amid lawsuits, confidentiality breach, and production scaling doubts.

POET Technologies raised $400 million in late April to fund a massive expansion of its photonics manufacturing, yet the stock now changes hands well below the $21 issue price of that placement. Shares have been caught between a punishing legal battle, the fallout from a broken confidentiality agreement, and a market that is demanding proof of production before rewarding the company’s AI-driven narrative.

The capital injection came via the issuance of 19,047,620 new shares along with warrants for the same number of shares, each exercisable at $26.25 over three years. A single institutional investor funded the entire round. Management plans to channel the proceeds into wafer fabrication, optical engine assembly, targeted acquisitions, and research and development — aiming to roughly decuple production capacity by 2027. For now, however, the discounted share price signals that investors see substantial execution risk in scaling up from current levels.

That gap between ambition and delivery was laid bare on a recent Tuesday when the broader semiconductor sector hit new highs but POET headed in the opposite direction. The iShares Semiconductor ETF climbed $33 to $570.09, the VanEck Semiconductor ETF rose to $602.14, and the Philadelphia Semiconductor Index set an all-time peak. POET opened at $15.00 and slid to $13.35 on volume of more than 46 million shares, a stark departure from the industry tailwind.

The legal turmoil that has dogged the stock stems from a single interview given by Chief Financial Officer Thomas Mika. In that conversation, Mika disclosed a business relationship with Marvell Technology, which had recently acquired Celestial AI — a customer of POET. The revelation violated a confidentiality agreement, prompting Marvell to cancel all orders related to Celestial AI. On April 27, the stock collapsed from around $15 to $7.95 in a single session, a drop of 47.3%.

Multiple US law firms — including Kessler Topaz Meltzer & Check, Faruqi & Faruqi, Pomerantz LLP, Levi & Korsinsky, and Bernstein Liebhard — have since filed class-action lawsuits. The complaints allege that POET misrepresented its status as a Passive Foreign Investment Company and that the firm breached its own stated confidentiality policies. The class period runs from April 1 to April 27, 2026, and the deadline for investors to apply as lead plaintiff is June 29.

After the crash, the stock staged a recovery that took it as high as $20.81 on May 14, only to give back a chunk of those gains. On the most recent trading day, shares oscillated between $14.32 and $15.40 on volume of roughly 34 million — well below the daily average of 74 million. Adding a layer of volatility, Defiance ETFs launched the Defiance Daily Target 2X Long POET ETF (ticker: POEL), which aims to double the daily move in the underlying stock, amplifying swings without altering fundamentals.

Those fundamentals remain thin. POET generated revenue of about $1.07 million over the trailing period, giving it a price-to-sales ratio above 2,200. EBITDA for 2025 came in at negative $76 million, and both return on equity and return on total capital stood at worse than minus 80%. The entire equity story rests on future growth — on the promise that the $400 million cash cushion can be converted into scalable manufacturing, reliable optical engines, and eventually meaningful revenue.

Whether that promise holds will become clearer in the coming months. The next production and order announcements will show whether the stock can close the gap to the $21 placement price — or whether the discount widens. Before any of that, investors have a hard deadline: June 29, when the court will name lead plaintiffs in a class action that could shape the company’s financial and legal trajectory for years.